Iscar for Supplemental Care in Stage IV Lung Cancer

National Center for Complementary and Integrative Health (NCCIH)36 enrolled

Overview

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

See Brief Summary

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lung Cancer

Interventions

IscarDRUG

mistletoeDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stage IV NSCLC patients who receive standard chemotherapy Exclusion criteria: * Known allergy to Viscum Album L. * Concomitant use of other mistletoe products * Concomitant use of mushroom glucan and proteoglycan extracts * Concomitant use of thymus extract products * Inability to self-report quality of life utilizing assessment tools * Ongoing steroid or ACTH therapy * Co-morbid immunocompromised state * Pregnancy * Participation in other clinical trials

Locations (1)

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.